Grant Bailey, MD
Cardiovascular Disease · Littleton, CONPI 1881919660
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,460 of the $87,996 with a category attached, or 63.0%. 43 manufacturers reported payments, led by Boehringer Ingelheim at 35.3% of the total. Reporting peaked in 2019 at $38,493 and has fallen 72.9% since, to $10,420 in 2025. Among cardiovascular disease clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 798 payments — averaging $110.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$31K
- Amarin Pharma, Inc.$18K
- Lilly USA, LLC$11K
- E.r. Squibb & Sons, L.L.C.$5K
- Edwards Lifesciences$4K
- Abbott$4K
- plus $15K from 37 others
Across 9 payments — averaging $11,166 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$100K
What the payments were for
- Consulting fees$7,4158%
- Speaking & faculty fees$55,46063%
- Travel & lodging$4,1275%
- Food & beverage$20,84124%
- Education$1530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$41,053
- Vascepa$17,331
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$2,450
- Mitra Clip system$1,200
- Barostim Neo System$845
- OPTIMIZER$628
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$557
- FFRct$443
- EVOQUE$396
- LifeVest$294
- SYMPLICITY G3$292
- WATCHMAN Access System$273
- Edwards SAPIEN 3 Transcatheter Heart Valve$247
- Repatha$243
- CARDIOMEMS$175
- Cleerly Ischemia$165
- Cleerly Labs$165
- GENERAL TACHY$147
- remede System$132
- Ozempic$125
How this compares
$87,996 in reported general payments places this provider in the 95th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 415 | $528,557 |
| VyndamaxTafamidis | 14 | $362,694 |
| CamzyosMavacamten | 43 | $343,023 |
| Repatha SureclickEvolocumab | 197 | $235,488 |
| JardianceEmpagliflozin | 149 | $215,853 |
| XareltoRivaroxaban | 155 | $203,150 |
| FarxigaDapagliflozin Propanediol | 123 | $159,038 |
| EntrestoSacubitril/Valsartan | 69 | $119,110 |
| Praluent PenAlirocumab | 43 | $48,862 |
| VascepaIcosapent Ethyl | 31 | $24,114 |
| Rosuvastatin Calcium | 934 | $13,071 |
| Nebivolol Hcl | 180 | $12,429 |
| LivaloPitavastatin Calcium | 12 | $9,123 |
| Metoprolol Succinate | 579 | $7,462 |
| Ezetimibe | 351 | $6,997 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $828 | $891,251429 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $4,916 | $343,02343 claims |
| Boehringer IngelheimJardiance | $31,034 | $215,853149 claims |
| Johnson & JohnsonXarelto | $459 | $203,150155 claims |
| AstraZenecaFarxiga | $870 | $159,038123 claims |
| NovartisEntresto | $1,381 | $119,11069 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $156 | $9,12312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Littleton
- Richard CollinsLittleton$71K
- Arthur LeveneLittleton$15K
- Josephine Chou CatanzaroLittleton$11K
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
- Andrew FreemanDenver$454K
- William SauerAurora$365K
- Jeffrey BooneGreenwood Village$287K
- Rhonda MiyasakaAurora$128K
- Gregory SchwartzAurora$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.